Clinical trial · no report yet · Phase 2
SEAMARK
A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer
- NCT05217446 ↗
- Active, not recruiting
- Pfizer
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 5 | |
| YouTube | 1 |
The trial
ClinicalTrials.gov- Official title
- A PHASE 2, RANDOMIZED, OPEN-LABEL STUDY OF ENCORAFENIB AND CETUXIMAB PLUS PEMBROLIZUMAB VERSUS PEMBROLIZUMAB ALONE IN PARTICIPANTS WITH PREVIOUSLY UNTREATED BRAF V600E-MUTANT, MSI H/DMMR METASTATIC COLORECTAL CANCER
- Phase
- Phase 2
- Status
- Active, not recruiting
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- Encorafenib; Cetuximab; Pembrolizumab
- Arms
- Arm B: pembrolizumab · Active comparator
- Arm A: encorafenib, cetuximab and pembrolizumab · Experimental
- Enrollment
- 108
- Primary outcomes
- Progression-free Survival (PFS)
- Sponsor
- Pfizer with Merck Sharp & Dohme LLC, Merck KGaA, Darmstadt, Germany, Eli Lilly and Company
- Start
- Jul 11, 2022
- Primary completion
- Jun 19, 2026
- Results posted
- No
- Registry record
- NCT05217446 · updated Jul 31, 2026
Publications
linked from the registry- Elez E, Kopetz S, Tabernero J, Bekaii-Saab T, Taieb J, Yoshino T, Manji G, Fernandez K, Abbattista A, Zhang X, Morris VK. SEAMARK: phase II study of first-line encorafenib and cetuximab plus pembrolizumab for MSI-H/dMMR BRAFV600E-mutant mCRC. Future Oncol. 2024 Apr;20(11):653-663. doi: 10.2217/fon-2022-1249. Epub 2023 Oct 10. PubMed 37815847